Clinical trial · Interventional
Fibroscan Study in HCC
A Study to Evaluate the Impact of Liver Stiffness on Treatment Outcome of Hepatocellular Carcinoma
NCT01796145CI-TRIAL-00097249active not recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In patients with HCC undergoing therapy 1. We aim to determine the prognostic significance of liver stiffness in patients with HCC 2. We aim to determine the rate and severity of complications of treatment and its association with liver stiffness in patients with HCC
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Child's A to C Cirrhosis | — | UNRESOLVED | — |
| Confirmed Diagnosis of Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.85 |
| Patients Who Are Scheduled to Undergo Transarterial Chemobolization, Systemic Therapy Surgery | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Fibroscan | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- TACE
- interventionNames
- Other: Fibroscan
- type
- EXPERIMENTAL
- label
- Systemic Therapy
- interventionNames
- Other: Fibroscan
- type
- EXPERIMENTAL
- label
- Surgery
- interventionNames
- Other: Fibroscan
Primary outcomes (1)
- measure
- Overall survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Clinical diagnosis of HCC * Patients who are scheduled to undergo therapy, either TACE systemic therapy or surgery 1. For TACE cohort, patients undergoing first cycle TACE are eligible. 2. For systemic therapy cohort, patients undergoing first-line systemic therapy are eligible. 3. For surgery cohort, patient undergoing surgery are eligible. * Prior surgery or loco-ablative therapy (e.g. Radiofrequency ablation, microwave, percutaneous ethanol injection) is allowed * Child's A to Child's C liver function Exclusion Criteria: * ECOG performance status \> 2 * Poorly controlled ascites
References
Publications (0)
Data not yet available
No reference posted for this study.